DexCom (DXCM)
(Delayed Data from NSDQ)
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights: DexComm, Forterra, Vista Outdoor, Hibbett Sports and Target
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DexComm, Forterra, Vista Outdoor, Hibbett Sports and Target
DexCom, Inc. (DXCM) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor DexCom, Inc. (DXCM).
5 Best Bets in View Before the Curtain Falls on November
by Zacks Equity Research
Solid economic data, favorable earnings reports and subsiding trade war anxiety bump up stocks in November. Here are top five momentum stocks that are poised to grow.
6 Top Momentum Stocks in November With More Room to Run
by Nalak Das
A temporary trade truce between the United States and China will bolster business confidence and stabilize overall U.S. economic growth.
Top Ranked Momentum Stocks to Buy for November 29th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 29th
5 Screaming Hot Strong Buy Stocks
by David Bartosiak
Do not let this pullback opportunity pass you by as the market has plenty of room to run.
Digital Diabetes Management Gains Momentum: 3 Stocks in Focus
by Trina Mukherjee
With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.
The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics
5 Best-Performing, Top-Ranked Growth Stocks of November
by Nalak Das
Wall Street's impressive bull run is likely to continue in the near term. At this stage, it will be prudent to invest in growth stocks with a favorable Zacks Rank.
5 Growth Stocks to Buy as U.S.-China Trade Tiff Eases
by Zacks Equity Research
The United States and China finally seem to be making progress on a phase one deal. Here are our five top growth stocks that are poised for fair returns.
MEDNAX (MD) Ties Up With Homestead to Expand in Florida
by Zacks Equity Research
MEDNAX (MD) collaborates with Associated Pediatricians of Homestead to provide clinical services and expand presence in Florida.
Dexcom (DXCM) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Dexcom (DXCM) gains from several positive developments.
Digital Health Gaining Momentum: 3 MedTech Stocks in Focus
by Trina Mukherjee
Digital health is committed to changing the face of healthcare as evident from its innovative solutions for the betterment of patients' lives.
Earnings Estimates Moving Higher for DexCom (DXCM): Time to Buy?
by Zacks Equity Research
DexCom (DXCM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The Zacks Analyst Blog Highlights: comScore, Communications Systems, Vista Outdoor, Forterra and DexCom
by Zacks Equity Research
The Zacks Analyst Blog Highlights: comScore, Communications Systems, Vista Outdoor, Forterra and DexCom
5 Winning Stocks Halfway Through Q4
by Zacks Equity Research
We have highlighted stocks that have done well so far in the fourth quarter and have room to scale higher in the near future.
BD's Onclarity HPV PMA Submission to Boost Women's Health
by Zacks Equity Research
Becton, Dickinson (BDX) offers a wide range of next-generation solutions in the field of cervical, ovarian and breast cancer.
San Gorgonio Hospital Picks Allscripts Sunrise Community Care
by Zacks Equity Research
Allscripts' (MDRX) Sunrise Community Care is an Azure-hosted platform offering clinical, financial and ambulatory content.
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
by Sanghamitra Saha
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
NextGen's Medfusion Buyout to Improve Patient Experience
by Zacks Equity Research
NextGen (NXGN) showcases new capabilities and services for its flagship NextGen Enterprise platform.
5 Relative Price Strength Stocks to Buy for Optimum Returns
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Dexcom, Fortinet and Agnico Eagle
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Dexcom, Fortinet and Agnico Eagle
A Struggle to Find Revenue Growth: Global Week Ahead
by John Blank
About 90% of S&P 500 companies have reported results as of Friday, Nov. 8th. 72.5% have beaten EPS estimates. Only 57.9% beat revenue estimates. A low Q3 revenue beat number (57.8%) is worrisome!
What Makes DexCom (DXCM) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.